Furthermore, with the identification of rearranged during transfection (RET) mutations in some FTC cases, selective RET inhibitors are being explored as potential treatment options, personalizing therapy based on genetic profiling [51]. This evidence concerns the gene RET and thyroid cancer, nonmedullary, 2.